Good Phase III results for Pfizer’s Tafamidis

Pfizer yesterday night announced that its investigational therapy Tafamidis reduces mortality in patients with a rare heart disease (ATTR-ACT). The statement is supported by positive results from the Phase III ATTR-ACT clinical trial, conducted on 441 patients. According to experts, Tafamidis could generate $130m per year once on the market, which could happen in record time, since FDA last June granted tadamidis a ‘fast track’ designation.

(Source: Pfizer)